Myrbetriq and Rubraca drug interactions - a phase IV clinical study of FDA data
Summary:
Drug interactions are reported among people who take Myrbetriq (mirabegron) and Rubraca (rucaparib camsylate). Common drug interactions include fatigue among females and asthenia among males.
The phase IV clinical study analyzes what interactions people have when they take Myrbetriq and Rubraca. It is created by eHealthMe based on reports of 12 people who take the same drugs from the FDA, and is updated regularly.
What is Myrbetriq?
Myrbetriq has active ingredients of mirabegron. It is often used in urge incontinence. eHealthMe is studying from 33,658 Myrbetriq users. Check the latest studies of Myrbetriq.
What is Rubraca?
Rubraca has active ingredients of rucaparib camsylate. eHealthMe is studying from 10,770 Rubraca users. Check the latest studies of Rubraca.
12 people who take Myrbetriq and Rubraca together, and have interactions are studied.
What are the common drug interactions of Myrbetriq and Rubraca, by gender? *:
female:
- Fatigue (feeling of tiredness)
- Abdominal discomfort
- Nausea (feeling of having an urge to vomit)
- Drug intolerance (drug sensitivity)
- Malignant neoplasm progression (cancer tumour came back)
- Abdominal pain upper
- Dysgeusia (disorder of the sense of taste)
male:
- Asthenia (weakness)
- Constipation
- Haemorrhage subcutaneous (bleeding from skin)
- Blood iron decreased
- Death
- Syncope (loss of consciousness with an inability to maintain postural tone)
- Urinary bladder haemorrhage (urinary bladder bleeding)
- Dehydration (dryness resulting from the removal of water)
- Nausea (feeling of having an urge to vomit)
- Pneumonia
What are the common drug interactions of Myrbetriq and Rubraca, by age (0-1 to 60+)? *:
0-1:
n/a
2-9:
n/a
10-19:
n/a
20-29:
n/a
30-39:
n/a
40-49:
n/a
50-59:
n/a
60+:
- Nausea (feeling of having an urge to vomit)
- Asthenia (weakness)
- Dyspnoea (difficult or laboured respiration)
- Haemorrhage subcutaneous (bleeding from skin)
- Abdominal discomfort
- Malignant neoplasm progression (cancer tumour came back)
- Urinary bladder haemorrhage (urinary bladder bleeding)
- Constipation
- Dehydration (dryness resulting from the removal of water)
- Pneumonia
What are the existing conditions these people have? *
- Prostate Cancer: 7 people, 58.33%
- Ovarian Cancer (cancer of ovary): 4 people, 33.33%
- Metastases To Liver (cancer spreads to liver): 1 person, 8.33%
* Approximation only. Some reports may have incomplete information.
Do you take Myrbetriq and Rubraca?
- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously
Related studies:
Effectiveness of, side effects of, and alternative drugs to the 2 drugs:
Browse all drug interactions of Myrbetriq and Rubraca:
a b c d e f g h i j k l m n o p q r s t u v w x y zSub-studies by gender and age:
Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Browse all side effects of Myrbetriq:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all side effects of Rubraca:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all interactions between Myrbetriq and drugs from A to Z:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all interactions between Rubraca and drugs from A to Z:
a b c d e f g h i j k l m n o p q r s t u v w x y zHow the study uses the data?
The study uses data from the FDA. It is based on mirabegron and rucaparib camsylate (the active ingredients of Myrbetriq and Rubraca, respectively), and Myrbetriq and Rubraca (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Cardiac Failure Chronic and Epilepsy - 3 seconds ago
- Could Aricept cause Ill-Defined Disorder? - 12 seconds ago
- Could Rebif cause Facial Spasm? - 23 seconds ago
- Could Buspirone Hcl cause Withdrawal Syndrome? - 29 seconds ago
- Could Sodium Chloride cause Systemic Lupus Erythematosus? - 40 seconds ago
- Could Darzalex cause Mucosal Inflammation? - 42 seconds ago
- Drug interactions of Abraxane and Naprosyn - 43 seconds ago
- Could Lunesta cause Dyspnea? - 43 seconds ago
- Quercetin-3-Rutinoside vs. Mucinex, side effect and effectiveness comparison - 47 seconds ago
- Drug interactions of Metoprolol Succinate and Lunesta - 49 seconds ago